Table 2 Summarization of neurological status and details pertaining to COVID-19 symptomatology and behavior of suspected or confirmed COVID-19 cohort
Child (n = 11) (%) | Adult (n = 3) (%) | Total (n = 14) (%) | |
|---|---|---|---|
1. Symptomatology related to COVID-19 | |||
(a) Fever | 100 | 100 | 100 |
(b) Others | |||
I. Sore throat | 90.9 | 66.7 | 85.7 |
II. Dry cough | 45.5 | 100 | 57.1 |
III. Dyspnea | 0 | 0 | 0 |
IV. Pain abdomen | 9.1 | 0 | 7.1 |
V. Diarrhea | 27.3 | 33.3 | 28.6 |
VI. Loss of smell | 36.4 | 100 | 50.0 |
VII. Loss of taste | 18.2 | 100 | 35.7 |
VIII. Headache | 27.3 | 100 | 42.9 |
IX. Red eyes | 0 | 0 | 0 |
X. Myalgia | 81.8 | 100 | 88.9 |
XI. Skin rashes | 0 | 0 | 0 |
2. Involvement of family members | 63.6 | 66.7 | 64.4 |
3. History of contact with COVID-19 patients | 63.6 | 100 | 71.4 |
4. Travel history | 0 | 66.7 | 14.3 |
5. Hospitalization | 9.1 | 0 | 7.1 |
6. Residence in containment zone | 100 | 100 | 100 |
7. Co-morbidities | |||
(a) Hypertension | 0 | 66.7 | 14.3 |
(b) Type II Diabetes Mellitus | 0 | 33.3 | 7.1 |
(c) Hypothyroidism | 0 | 0 | 0 |
(d) Renal dysfunction | 0 | 0 | 0 |
(e) Cardiac dysfunction | 0 | 0 | 0 |
(f) Liver dysfunction | 0 | 0 | 0 |
(g) Hematological dysfunction | 9.1 | 0 | 7.1 |
8. Neurological symptom (worsening or new onset) | |||
(a) Fixed motor weakness | 9.1 | 0 | 7.1 |
(b) Seizure | 18.2 | 0 | 14.3 |
(c) Headache | 9.1 | 33.3 | 14.3 |
(d) Transient ischemic attack | 45.5 | 0 | 35.7 |
(e) Cognitive and behavioral symptoms | 0 | 0 | 0 |
(f) Visual symptoms | 0 | 0 | 0 |
(g) Extra-pyamidal symptoms | 0 | 0 | 0 |